Skip to content
Screener

Haemonetics HAE Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

TFX
TeleflexTFX
$1.41B-18.4%
ICU Medical logo
ICU MedicalICUI
$717.02M+21.5%
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
InfuSystem Holdings logo
InfuSystem HoldingsINFU
ITG
Integer HoldingsITGR

Other financials

Income statement

See full
Revenue$339.4M+5.6%
Gross profit$202.8M+5.5%
Operating income$57.5M+6.7%
Net income$33.0M-3.0%
EPS (diluted)$0.72+2.9%

Balance sheet

See full
Cash & equivalents$223.4M-23.7%
Total debt$1.2B-4.1%
Total equity$837.1M-5.1%
Total assets$2.4B-3.9%

Cash flow

See full
Operating cash flow$52.3M+201%
CapEx$7.9M+111%
Free cash flow$44.4M+226%

Valuation

See full
Market cap$4B+58.1%
Enterprise value$4.95B+43.0%
P/E26.6×-10.9×
P/S+1.1×

Profitability

See full
Gross margin59%+2.1pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin21.5%+7.5pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.4×0.0×
Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:09 AM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000313143-26-000120
Line itemJune 27, 2026March 28, 2026
Prepaid expenses and other current assets64,63866,214
Total current assets810,832834,879
Property, plant and equipment, net303,778305,761
Intangible assets, less accumulated amortization of $374,828 as of June 27, 2026 and $363,763 as of March 28, 2026434,512447,655
Goodwill656,884656,368
Deferred tax asset9,4349,521
Other long-term assets149,960141,741
Total assets$2,365,400$2,395,925

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's finite-lived intangible assets, accumulated amortization?
Haemonetics (HAE) reported finite-lived intangible assets, accumulated amortization of $374.83M in Q2 2026.
How has Haemonetics's finite-lived intangible assets, accumulated amortization changed year-over-year?
Haemonetics's finite-lived intangible assets, accumulated amortization increased by 13.4% year-over-year, from $330.65M to $374.83M.
What is the long-term trend for Haemonetics's finite-lived intangible assets, accumulated amortization?
Over 5 years (2021 to 2026), Haemonetics's finite-lived intangible assets, accumulated amortization has grown at a 2.6% compound annual growth rate (CAGR), from $320.64M to $363.76M.
What does finite-lived intangible assets, accumulated amortization mean?
Finite-Lived Intangible Assets, Accumulated Amortization

Ask your AI about Haemonetics's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude